Rajesh Vedhanayaki

Madurai, TN, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Journal: Ophthalmology science

Published: July 15, 2025

Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Journal: Ocular immunology and inflammation

Published: August 27, 2024

Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.

Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.

Journal: American journal of ophthalmology

Published: December 28, 2023

Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.

Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.

Journal: Ocular immunology and inflammation

Published: February 07, 2023

Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.

Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.

Journal: Ocular immunology and inflammation

Published: January 26, 2023

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.

Journal: Journal of ophthalmic inflammation and infection

Published: November 09, 2022

Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Journal: Ophthalmology

Published: December 14, 2021

Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.

Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.

Journal: Ophthalmology

Published: October 12, 2021

Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.

Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.

Journal: Ophthalmology

Published: November 27, 2020

Diagnostic Markers in Ocular Sarcoidosis in A High TB Endemic Population - A Multicentre Study.

Diagnostic Markers in Ocular Sarcoidosis in A High TB Endemic Population - A Multicentre Study.

Journal: Ocular immunology and inflammation

Published: September 02, 2020

Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.

Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.

Journal: Ocular immunology and inflammation

Published: August 12, 2020

An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults.

An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults.

Journal: Ocular immunology and inflammation

Published: April 15, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026